MDGL
NASDAQ · Biotechnology
Madrigal Pharmaceuticals Inc
$509.76
-3.67 (-0.71%)
Financial Highlights (FY 2026)
Revenue
984.95M
Net Income
-296,267,510
Gross Margin
94.1%
Profit Margin
-30.1%
Rev Growth
—
D/E Ratio
0.56
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 94.1% | 67.1% | 67.1% | 67.1% |
| Operating Margin | -31.6% | -21.6% | -21.3% | -20.6% |
| Profit Margin | -30.1% | -30.9% | -31.4% | -30.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 984.95M | 3.52B | 3.21B | 3.39B |
| Gross Profit | 927.23M | 2.36B | 2.15B | 2.28B |
| Operating Income | -311,243,229 | -759,164,813 | -685,033,522 | -697,563,334 |
| Net Income | -296,267,510 | -1,086,916,353 | -1,008,552,409 | -1,039,436,250 |
| Gross Margin | 94.1% | 67.1% | 67.1% | 67.1% |
| Operating Margin | -31.6% | -21.6% | -21.3% | -20.6% |
| Profit Margin | -30.1% | -30.9% | -31.4% | -30.6% |
| Rev Growth | — | +9.6% | -7.9% | +0.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.10B | 2.41B | 2.51B | 2.21B |
| Total Equity | 3.73B | 5.19B | 5.48B | 4.87B |
| D/E Ratio | 0.56 | 0.46 | 0.46 | 0.45 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -309,715,875 | -994,214,061 | -913,486,769 | -1,111,482,398 |
| Free Cash Flow | — | -874,407,524 | -958,278,915 | -784,321,183 |